XML 49 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCK BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2013
STOCK BASED COMPENSATION  
Schedule of stock based compensation expense

Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended March 31, 2012 and 2013 as shown in the following table (in $000s):

 

 

 

For the three months
ended March 31,

 

 

 

2012

 

2013

 

General and administrative

 

77

 

57

 

Research and development

 

17

 

15

 

Discontinued operations

 

8

 

 

Stock-based compensation costs before income taxes

 

102

 

72

 

Schedule of stock option activity

 

 

Cyclacel Pharmaceuticals, Inc.

 

Number of
options
outstanding

 

Weighted
average
exercise
price

 

Weighted
average
remaining
contractual
term (years)

 

Aggregate
intrinsic
value

 

Options outstanding at December 31, 2012

 

463,023

 

$

26.61

 

5.58

 

$

347

 

Granted

 

 

$

 

 

 

 

 

Exercised

 

 

$

 

 

 

 

 

Cancelled/forfeited

 

 

$

 

 

 

 

 

Options outstanding at March 31, 2013

 

463,023

 

$

26.61

 

5.33

 

292

 

Unvested at March 31, 2013

 

62,024

 

$

8.66

 

8.22

 

52

 

Vested and exercisable at March 31, 2013

 

400,999

 

$

29.39

 

4.88

 

240

 

Schedule of restricted stock units activity

 

 

 

 

Restricted Stock
Units

 

Weighted Average
Grant
Date Value Per Share

 

Non-vested at December 31, 2012

 

39,377

 

$

5.34

 

Granted

 

85,097

 

$

5.71

 

Non-vested at March 31, 2013

 

124,474

 

$

5.60